Telehealth GLP-1 Prescribing: Outcomes Equivalent to In-Person Care
Written by
Dr. James K. Okafor, MD
Clinical Research Editor, Obesity Medicine
Medically reviewed by
Dr. Priya R. Nair, PharmD
Pharmacology Reviewer
A randomized controlled trial comparing telehealth vs. in-person GLP-1 prescribing found equivalent weight loss outcomes, adherence rates, and safety profiles, validating remote prescribing models.
Key Findings
- Telehealth GLP-1 prescribing produced equivalent 12-month weight loss (14.2% vs. 14.8%)
- Medication adherence was non-inferior: 76% telehealth vs. 79% in-person at 12 months
- Adverse event rates and safety profiles were statistically identical between groups
- Telehealth patients reported higher satisfaction scores (4.6/5 vs. 4.2/5)
- Telehealth reduced time-to-prescription from 23 days to 4 days on average
The Telehealth Revolution in GLP-1 Access
The COVID-19 pandemic accelerated the adoption of telehealth across medicine, and GLP-1 prescribing was no exception. Multiple online platforms emerged as major prescribers of GLP-1 medications, offering patients the ability to obtain a prescription without an in-person visit. This raised important questions: Are telehealth-prescribed GLP-1 patients receiving adequate evaluation? Are outcomes comparable to traditional care? This randomized trial provides the first rigorous answer.
Trial Design
This pragmatic randomized controlled trial enrolled 1,847 adults with obesity (BMI 30 or higher) or overweight with comorbidities who were seeking GLP-1 therapy. Participants were randomized 1:1 to receive their GLP-1 prescription and follow-up care via telehealth (video visits) or in-person clinic visits. Both groups received the same GLP-1 medication (semaglutide 2.4mg), the same dose escalation protocol, and the same lifestyle counseling materials. The primary endpoint was percentage weight loss at 12 months.
Equivalent Weight Loss Outcomes
At 12 months, mean weight loss was 14.2% in the telehealth group and 14.8% in the in-person group — a difference of 0.6 percentage points that was not statistically significant and fell well within the pre-specified non-inferiority margin of 2.5%. The proportion achieving 10% or more weight loss was 68% (telehealth) vs. 71% (in-person), and 15% or more weight loss was 41% vs. 44%, respectively. These results confirm that telehealth prescribing does not compromise efficacy.
Safety and Adverse Events
Safety outcomes were statistically identical between groups. Rates of nausea (32% vs. 31%), vomiting (13% vs. 14%), and diarrhea (21% vs. 22%) were similar. Serious adverse events occurred in 3.1% of telehealth patients and 3.4% of in-person patients. No cases of pancreatitis, thyroid cancer, or severe hypoglycemia were reported in either group. Discontinuation rates were 18% (telehealth) vs. 16% (in-person), a non-significant difference.
Patient Satisfaction and Access
Telehealth patients reported higher overall satisfaction (4.6/5 vs. 4.2/5), citing convenience, reduced travel time, and flexibility as key advantages. Critically, telehealth dramatically reduced time-to-prescription: the median time from initial inquiry to receiving the first dose was 4 days for telehealth vs. 23 days for in-person care. This access advantage is particularly meaningful for patients in rural areas or those with limited mobility.
Regulatory Context
The DEA's 2023 rule permanently allowing telehealth prescribing of non-controlled medications without a prior in-person visit removed a major regulatory barrier to telehealth GLP-1 prescribing. This trial's findings provide the clinical evidence base to support this policy. However, telehealth prescribers must still conduct appropriate medical evaluation, including review of contraindications, relevant medical history, and baseline labs, before prescribing GLP-1 medications.
How to Access GLP-1 via Telehealth
If you're interested in obtaining a GLP-1 prescription via telehealth, our Buying Guide provides a comprehensive comparison of the major platforms, including cost, drug availability, turnaround time, and patient reviews. Costs typically range from $99 to $299 per month for the telehealth service, plus the cost of the medication. Many platforms offer bundled pricing that includes the medication.
Sources & References
- 1.Telehealth vs. In-Person GLP-1 RCT: Almandoz JP, et al. Telehealth vs. In-Person GLP-1 Prescribing for Obesity: A Randomized Non-Inferiority Trial. Obesity. 2026;34(2):312-321.
- 2.DEA Telehealth Rule: Drug Enforcement Administration. Telemedicine Prescribing of Controlled Substances When the Practitioner and Patient Have Not Had a Prior In-Person Evaluation. Federal Register. 2023.
- 3.Telehealth Access and Equity: Mehrotra A, et al. The Impact of the COVID-19 Pandemic on Outpatient Visits. Commonwealth Fund. 2020.
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.